CSL (OTCMKTS:CSLLY) Shares Gap Down – What’s Next?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $54.02, but opened at $51.08. CSL shares last traded at $51.28, with a volume of 3,160 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada cut CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. Finally, Canaccord Genuity Group upgraded shares of CSL from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, CSL presently has an average rating of “Moderate Buy”.

CSL Stock Down 1.6%

The company’s 50 day moving average price is $58.78 and its 200 day moving average price is $63.68. The company has a quick ratio of 1.12, a current ratio of 2.46 and a debt-to-equity ratio of 0.50.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.